Guselkumab Shows Psoriasis Benefit in Darker Skin Tones - Summary - MDSpire
From the Journals

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

  • By

  • Andrea Surnit

  • May 14, 2026

  • 3 min

Share

A phase IIIb VISIBLE Cohort A trial reveals that Guselkumab significantly improves skin clearance and symptoms in non-White patients with moderate to severe plaque psoriasis compared to placebo. Among 103 participants from the US and Canada, 74% achieved clear skin after 16 weeks versus none in the placebo group, with many maintaining improvements up to week 48. The treatment was associated with adverse events in 38% of patients but serious events were rare. The findings highlight Guselkumab’s effectiveness across diverse skin tones.

Original Source(s)

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

  • by Andrea Surnit

  • May 14, 2026

Related Content

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.

AOPT Plus Collagen May Ease Rosacea

Randomized trial suggests better short-term outcomes and lower recurrence at 24 weeks